Profile
Rachel Curtis Gravesen formerly worked at Novo Nordisk A, as Communications Manager, Genmab A, as Senior VP-Investor Relations & Communications from 2011 to 2019, and Pharmaceutical Development Center, as Vice President-Investor Relations.
Ms. Gravesen received her undergraduate degree from City University London and graduate degree from the University of Cambridge.
Rachel Curtis Gravesen active positions
| Companies | Position | Start |
|---|---|---|
| CESSATECH A/S | Director/Board Member | 16/03/2022 |
Former positions of Rachel Curtis Gravesen
| Companies | Position | End |
|---|---|---|
| GENMAB A/S | Investor Relations Contact | 10/03/2019 |
| NOVO NORDISK A/S | Public Communications Contact | - |
Pharmaceutical Development Center
Pharmaceutical Development Center Miscellaneous Commercial ServicesCommercial Services Researches and develops pharmaceutical products | Public Communications Contact | - |
Training of Rachel Curtis Gravesen
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Novo Nordisk A/S
Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Genmab A/S
Genmab A/S BiotechnologyHealth Technology Operates as a biotechnology company for improving the lives of people with cancer and serious diseases through antibody medicines | Health Technology |
University of Cambridge
University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pharmaceutical Development Center
Pharmaceutical Development Center Miscellaneous Commercial ServicesCommercial Services Researches and develops pharmaceutical products | Commercial Services |
City University London
City University London Functions as a College/University | |
Cessatech A/S
Cessatech A/S Develops and commercializes medicines for children for the treatment of pediatric acute pain |
- Stock Market
- Insiders
- Rachel Curtis Gravesen
















